The Author(s) 2013. This article is published with open access at Springerlink.com Background The burden of invasive meningococcal dis-ease is substantial in older adults in whom the case fatality rate is high. Travelers to regions with high rates of meningococcal disease, such as Hajj pilgrims, are at increased risk of meningococcal infection, and disease transmission from travelers to their close contacts has been documented. In younger individuals, meningococcal con-jugate vaccines offer advantages over polysaccharide vac-cines in terms of duration of protection and boostability, and induction of herd immune effects through reductions in nasopharyngeal carriage of meningococci. To date, few data are available evaluating meningococcal conjugate vaccine use in adults [55 years of age
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.